Last update 12 Nov 2026

Nintedanib esylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CYNEDIV, Intedanib, NDNB
+ [29]
Action
antagonists, inhibitors
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFRs antagonists(Fibroblast growth factor receptors antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Drug Highest PhaseApproved
First Approval Date
United States (15 Oct 2014),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC33H39N5O7S
InChIKeyMMMVNAGRWOJNMW-FJBFXRHMSA-N
CAS Registry656247-18-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell Carcinoma
Australia
01 Sep 2015
metastatic non-small cell lung cancer
Australia
01 Sep 2015
Recurrent Non-Small Cell Lung Cancer
Australia
01 Sep 2015
Interstitial lung disease due to systemic disease
European Union
14 Jan 2015
Interstitial lung disease due to systemic disease
Iceland
14 Jan 2015
Interstitial lung disease due to systemic disease
Liechtenstein
14 Jan 2015
Interstitial lung disease due to systemic disease
Norway
14 Jan 2015
Progressive fibrotic interstitial lung disease
European Union
14 Jan 2015
Progressive fibrotic interstitial lung disease
Iceland
14 Jan 2015
Progressive fibrotic interstitial lung disease
Liechtenstein
14 Jan 2015
Progressive fibrotic interstitial lung disease
Norway
14 Jan 2015
Adenocarcinoma of Lung
European Union
21 Nov 2014
Adenocarcinoma of Lung
Iceland
21 Nov 2014
Adenocarcinoma of Lung
Liechtenstein
21 Nov 2014
Adenocarcinoma of Lung
Norway
21 Nov 2014
Adenocarcinoma of Lung
United Kingdom
21 Nov 2014
Idiopathic Pulmonary Fibrosis
United States
15 Oct 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic interstitial lung diseaseNDA/BLA
European Union
22 Feb 2024
Lung Diseases, InterstitialNDA/BLA
United States
25 Jul 2023
PterygiumPhase 3
United States
30 Jun 2022
PterygiumPhase 3
China
30 Jun 2022
PterygiumPhase 3
Australia
30 Jun 2022
PterygiumPhase 3
India
30 Jun 2022
PterygiumPhase 3
New Zealand
30 Jun 2022
SclerodermaPhase 3
United States
05 Dec 2017
SclerodermaPhase 3
Japan
05 Dec 2017
SclerodermaPhase 3
Argentina
05 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
36
eqslhjuquy(ucmlqzrjzl) = diarrhea in 18 (50.0%), dose reduction in 23 (63.9%), and permanent discontinuation in only 2 (5.6%). chmtcgexzc (pxtetrrkwf )
Positive
06 Nov 2026
Phase 2
49
lmogntovcv(zvmchzphfb) = every component achieved ≥88.9% top-2-box satisfaction, and most components reached ≥93% twyuziynrn (vrowllrmrj )
Positive
06 Nov 2026
Not Applicable
1,530
paueuqlxqa(jdjdurnoaz) = dybybjjnxc fkqzmmzqlf (vqarsjwarl )
Positive
06 Nov 2026
paueuqlxqa(jdjdurnoaz) = hkyulujbod fkqzmmzqlf (vqarsjwarl )
Not Applicable
20
Nintedanib or pirfenidone
ktgdqwqrht(xhixfhupcn) = myaecuvcbe iwdaqktldo (ixqraxadhp )
Positive
06 Nov 2026
Not Applicable
86
(CTD-PPF)
xqqyolnvyr(tesvlbxhuq) = At least one adverse event occurred in most patients, mainly diarrhoea and nausea. Weight and appetite loss were more frequent in P-PPF. gioyejniwg (vwuaisjhaa )
Positive
28 Oct 2026
(P-PPF)
Not Applicable
274
nejywnoayh(nkibztgcad) = efakkqmosj wpnmbyvarl (tgydhoylai )
Positive
28 Oct 2026
(SARD-ILD/PPF)
nejywnoayh(nkibztgcad) = nvjqlixgik wpnmbyvarl (tgydhoylai )
Not Applicable
182
znaioweswo(clgydtedtz) = In multivariable analysis, BMI was no longer an independent predictor (p=0.106) qbbolmtynx (erypeopdqq )
Positive
28 Oct 2026
Not Applicable
166
btmjmwcrag(xxoepmnzmp) = Main adverse events were gastrointestinal (68.8%) and hepatic (23.4%). uovepoqfet (irewmbbvzz )
Positive
28 Oct 2026
Not Applicable
542
(Progression Group)
gffrafwgnt(tnbxqolrkg) = Lower baseline body mass index (BMI) (OR:0.88, 95%CI:0.83-0.93, p<0.001) were independently associated with disease progression whtvtwibts (bsywalsnty )
Positive
28 Oct 2026
(Non-Progression Group)
Not Applicable
158
siryazlpsq(aeanqhsnor) = dugsmdqsxr dlwcgfxqpu (rksajjyehu )
Positive
28 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free